241 related articles for article (PubMed ID: 30653242)
1. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
[TBL] [Abstract][Full Text] [Related]
2. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
[TBL] [Abstract][Full Text] [Related]
3. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.
Ständer S; Kwon P; Hirman J; Perlman AJ; Weisshaar E; Metz M; Luger TA;
J Am Acad Dermatol; 2019 May; 80(5):1395-1402. PubMed ID: 30894279
[TBL] [Abstract][Full Text] [Related]
4. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
5. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
6. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial.
Yosipovitch G; Ständer S; Kerby MB; Larrick JW; Perlman AJ; Schnipper EF; Zhang X; Tang JY; Luger T; Steinhoff M
J Am Acad Dermatol; 2018 May; 78(5):882-891.e10. PubMed ID: 29462657
[TBL] [Abstract][Full Text] [Related]
7. Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.
Jacob D; Busciglio I; Burton D; Halawi H; Oduyebo I; Rhoten D; Ryks M; Harmsen WS; Camilleri M
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G505-G510. PubMed ID: 28814387
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.
Jiménez Gallo D; Albarrán Planelles C; Linares Barrios M; Fernández Anguita MJ; Márquez Enríquez J; Rodríguez Mateos ME
Dermatol Ther; 2014; 27(3):178-82. PubMed ID: 24517320
[TBL] [Abstract][Full Text] [Related]
9. The NK1 receptor antagonist serlopitant for treatment of chronic pruritus.
Ständer S; Spellman MC; Kwon P; Yosipovitch G
Expert Opin Investig Drugs; 2019 Aug; 28(8):659-666. PubMed ID: 31272246
[No Abstract] [Full Text] [Related]
10. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
[TBL] [Abstract][Full Text] [Related]
11. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation.
Agelopoulos K; Rülander F; Dangelmaier J; Lotts T; Osada N; Metze D; Luger TA; Loser K; Ständer S
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2371-2379. PubMed ID: 31442331
[TBL] [Abstract][Full Text] [Related]
12. Aprepitant in the Treatment of Subacute Sclerosing Panencephalitis: A Randomized, Double-Blind, Placebo-Controlled Study.
Oncel I; Sancar M; Konuskan B; Arioz F; Tezcan S; Arman-Kandirmaz E; Parlak S; Gumeler E; Anlar B
Pediatr Neurol; 2020 Sep; 110():59-63. PubMed ID: 32718528
[TBL] [Abstract][Full Text] [Related]
13. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.
Ständer S; Siepmann D; Herrgott I; Sunderkötter C; Luger TA
PLoS One; 2010 Jun; 5(6):e10968. PubMed ID: 20532044
[TBL] [Abstract][Full Text] [Related]
14. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
[TBL] [Abstract][Full Text] [Related]
15. Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis.
Lönndahl L; Holst M; Bradley M; Killasli H; Heilborn J; Hall MA; Theodorsson E; Holmberg J; Nordlind K
Acta Derm Venereol; 2018 Mar; 98(3):324-328. PubMed ID: 29182791
[TBL] [Abstract][Full Text] [Related]
16. Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial.
Zic JA; Straka BT; McGirt LY; Nian H; Yu C; Brown NJ
JAMA Dermatol; 2018 Oct; 154(10):1221-1222. PubMed ID: 30140912
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial.
Chiou AS; Choi S; Barriga M; Dutt-Singkh Y; Solis DC; Nazaroff J; Bailey-Healy I; Li S; Shu K; Joing M; Kwon P; Tang JY
J Am Acad Dermatol; 2020 Jun; 82(6):1415-1421. PubMed ID: 31541747
[TBL] [Abstract][Full Text] [Related]
18. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
[TBL] [Abstract][Full Text] [Related]
19. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
Keller M; Montgomery S; Ball W; Morrison M; Snavely D; Liu G; Hargreaves R; Hietala J; Lines C; Beebe K; Reines S
Biol Psychiatry; 2006 Feb; 59(3):216-23. PubMed ID: 16248986
[TBL] [Abstract][Full Text] [Related]
20. Doxepin cream is not effective in reducing itch in burn scar patients: A multicenter triple-blind randomized clinical crossover trial.
Kwa KAA; Legemate CM; Pijpe A; Meij-de Vries A; Middelkoop E; van Baar ME; Breederveld RS; Nieuwenhuis MK
Burns; 2020 Mar; 46(2):340-346. PubMed ID: 31839501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]